|
Boston University Scleroderma Program, Doctor’s
Office Building, Boston University Medical Center, 720
Harrison Avenue, Boston, MA 02118
www.bumc.bu.edu/rheumatology/scleroderma/
Clinic Information:
Adult, adolescent and pediatric patients seen with systemic
and localized scleroderma
Hours: Monday–Friday, 9 a.m.–5 p.m.
dependent on individual doctor’s office hours.
Appointments: Mary Lou Kemp, 617-638-4312
Physician Inquiries: 617-638-4312 or 617-638-4486
Research Information:
Kim Tobin 617-638-4475 or
Kate Brennan 617-638-4486
| Studies |
Status |
| SCOT Study: Randomized, open-label, multi-center study of high-dose immunosuppressive therapy using total body irradiation, cyclophosphamide, ATGAM, and autologous transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the treatment of severe systemic sclerosis |
Active recruiting |
| SERAPHIN: A multicenter, double-blind, randomized, placebo controlled study to assess the effects of ACT-064992 in patients with symptomatic pulmonary arterial hypertension. |
Active recruiting |
| SERAPHIN OL: Long-term, single-arm (no placebo) open-label extension study of the SERAPHIN study, to assess the safety and tolerability of ACT-064992 in patients with symptomatic pulmonary arterial hypertension. |
Active recruiting |
| DISTOL-1: Digital ischemic lesions in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo controlled, multicenter study. |
Active recruiting |
| DISTOL-EXT: Digital ischemic lesions in scleroderma treated wtih oral treprostinil diethanolamine: an open-label extension study (no placebo). |
Active recruiting |
| DISTOL-PK Study: An evaluation of the pharmacokinetics and safety of fixed and escalating doses of oral treprostinil diethanolamine sustained release tablets in patients with systemic sclerosis. |
Active recruiting |
| DASATINIB: An open label trail to evaluate the safety of dasatinib in the treatment of scleroderma pulmonary interstitial fibrosis. |
Active recruiting |
| PHAROS: Pulmonary Hypertension Assessment Registry of Scleroderma. |
Active recruiting |
| REVEAL: Registry to evaluate early and long-term PAH disease management. |
Active recruiting |
| DETECT: An observational study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension. |
Active recruiting |
| Identification of biomarkers for disease activity and progression in scleroderma. |
Active recruiting |
| Provisional combined response index for patients with diffuse systemic sclerosis. |
Active recruiting |
Physicians Affiliated with
this Center:
- Robert Simms, M.D.
- Robert Lafyatis, M.D.
- Peter Merkel, M.D.
- Eugene Kissin, M.D.
- Paul Monach, M.D., Ph.D.
- Michael York, M.D.
|
